NCT01828008

Brief Summary

To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2013

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

April 6, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 10, 2013

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

April 10, 2013

Status Verified

January 1, 2013

Enrollment Period

2.1 years

First QC Date

April 6, 2013

Last Update Submit

April 9, 2013

Conditions

Lymphomas

Keywords

Mabtheracytokine induced killer cell

Outcome Measures

Primary Outcomes (1)

  • disease free survival

    5 years

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

the patients with CD20-positive Lymphomas

You may qualify if:

  • \- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

You may not qualify if:

  • \- to refuse the therapy and need not tolerate the therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
combination of anti-CD20 with CIK for refractory lymphomas

Study Record Dates

First Submitted

April 6, 2013

First Posted

April 10, 2013

Study Start

April 1, 2013

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

April 10, 2013

Record last verified: 2013-01